within Pharmacolibrary.Drugs.N_NervousSystem.N02A_Opioids.N02AA56_OxycodoneAndNaltrexone;

model OxycodoneAndNaltrexone
  extends Pharmacolibrary.Drugs.ATC.N.N02AA56;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>N02AA56</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Oxycodone and naltrexone is a fixed-dose combination medication used for the management of severe pain where an opioid analgesic is appropriate and abuse deterrence is needed. Oxycodone is an opioid agonist used for pain relief, while naltrexone is an opioid antagonist included to mitigate risk of abuse. The combination is marketed in certain formulations (e.g., extended-release tablets) with regulatory approval in some countries, but is not universally available worldwide.</p><h4>Pharmacokinetics</h4><p>No published pharmacokinetic models directly reporting PK parameters for the fixed-dose oxycodone and naltrexone combination tablet were found. The data below are estimated based on available PK data for oxycodone and naltrexone individually in healthy adults after oral administration.</p><h4>References</h4><ol><li><p>Thigpen, JC, et al., &amp; Harirforoosh, S (2019). Opioids: A Review of Pharmacokinetics and Pharmacodynamics in Neonates, Infants, and Children. <i>European journal of drug metabolism and pharmacokinetics</i> 44(5) 591–609. DOI:<a href=\"https://doi.org/10.1007/s13318-019-00552-0\">10.1007/s13318-019-00552-0</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/31006834/\">https://pubmed.ncbi.nlm.nih.gov/31006834</a></p></li><li><p>Gandelman, K, et al., &amp; Malhotra, B (2015). Effect of food on the pharmacokinetics of oxycodone and naltrexone from ALO-02, an extended release formulation of oxycodone with sequestered naltrexone. <i>Clinical pharmacology in drug development</i> 4(5) 370–376. DOI:<a href=\"https://doi.org/10.1002/cpdd.177\">10.1002/cpdd.177</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/27137146/\">https://pubmed.ncbi.nlm.nih.gov/27137146</a></p></li><li><p>Kleideiter, E, et al., &amp; Rengelshausen, J (2020). Evaluation of the effect of naltrexone coadministration on the pharmacokinetics of oxycodone in a randomized phase 1 clinical trial . <i>International journal of clinical pharmacology and therapeutics</i> 58(8) 439–448. DOI:<a href=\"https://doi.org/10.5414/CP203706\">10.5414/CP203706</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/32507128/\">https://pubmed.ncbi.nlm.nih.gov/32507128</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end OxycodoneAndNaltrexone;
